Analyst Reco. Organon & Co.

Equities

OGN

US68622V1061

Market Closed - Nyse Other stock markets 04:00:02 2024-06-07 pm EDT			5-day change	1st Jan Change
20.75 ^USD	+0.39%		-2.72%	+43.90%

May. 24	Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation	MT
May. 24	Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Raiises Price Target on Organon to $24 From $22, Maintains Overweight Rating	Apr. 29	MT
Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating	Apr. 09	MT
Goldman Sachs Adjusts Price Target on Organon to $18 From $16, Keeps Neutral Rating	Feb. 20	MT
Piper Sandler Adjusts Organon & Co.'s Price Target to $22 From $32, Maintains Overweight Rating	Nov. 22	MT
Goldman Sachs Downgrades Organon to Neutral From Buy, Cuts Price Target to $16 From $33	Nov. 03	MT
Morgan Stanley Adjusts Price Target on Organon to $22 From $27, Maintains Equal-Weight Rating	23-10-11	MT
Barclays Initiates Organon With Overweight Rating, Price Target is $28	23-09-21	MT
Morgan Stanley Adjusts Price Target on Organon to $27 From $25, Maintains Equal-Weight Rating	23-08-09	MT
Morgan Stanley Cuts Price Target on Organon to $25 From $26, Maintains Equal-Weight Rating	23-05-08	MT
Raymond James Starts Organon & Co. at Outperform With $33 Price Target	23-03-16	MT
Hot Wholesale Prices Print Saps Appetite for US Equities as Concern Mounts Rates Headed Higher	23-02-16	MT
Marketmind: Growth trumps rates	23-02-16	RE
Morgan Stanley Lowers Price Target for Organon to $24 From $27, Keeps Equalweight Rating	22-11-04	MT
BofA Securities Downgrades Organon to Underperform From Neutral, Adjusts Price Target to $25 From $37	22-10-14	MT
Morgan Stanley Lowers Organon & Co's Price Target to $27 From $35, Maintains Equalweight Rating	22-10-12	MT
Piper Sandler Upgrades Organon & Co. to Overweight From Neutral, Adjusts Price Target to $34 From $37	22-09-06	MT
Goldman Sachs Trims Organon & Co's Price Target to $38 From $41, Keeps Buy Rating	22-08-08	MT
BofA Securities Downgrades Organon to Neutral From Buy, Adjusts Price Target to $37 From $40	22-08-05	MT
Goldman Sachs Adjusts Price Target for Organon & Co to $41 From $42, Maintains Buy Rating	22-07-19	MT
Morgan Stanley Trims Organon & Co's Price Target to $34 From $35, Maintains Equalweight Rating	22-07-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Organon & Co.

Equities

OGN

US68622V1061

Analyst Reco.

Filters